HIV neutralizing antibody titer during structured treatment interruption of highly active antiretroviral therapy

AIDS

Volumn 26, Issue 11, 2012, Pages 1451-1452

  Nicastri, Emanuele ^a   Dori, Luca ^b   Buonomini, Anna R ^b   Tommasi, Chiara ^a   De Nardo, Pasquale ^a   Bellagamba, Rita ^a   Corpolongo, Angela ^a   Montano, Marco ^b   Sordillo, Pasquale ^b   Volpi, Antonio ^b   Sarmati, Loredana ^b   Andreoni, Massimo ^b  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS RNA;

ANTIBODY TITER; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DISEASE COURSE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LETTER; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STRUCTURED TREATMENT INTERRUPTION; THERAPY; TREATMENT DURATION; VIRUS LOAD; VIRUS NEUTRALIZATION;

ANTI-HIV AGENTS; ANTIBODIES, NEUTRALIZING; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; VIRAL LOAD;

EID: 84863709968     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283550b47     Document Type: Letter

References (3)

1. McLinden RJ, Paris RM, Polonis VR, Close NC, Su Z, Shikuma CM, et al. Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). AIDS 2012; 26:1452.
2. Sarmati L, Andreoni C, Nicastri E, Tommasi C, Buonomini A, D'Ettorre G, et al. Prognostic factors of long-term CD4R countguided interruption of antiretroviral treatment. J Med Virol 2009; 81:481-487.
3. Sarmati L, Nicastri E, el-Sawaf G, Ventura L, Salanitro A, Ercoli L, et al. Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir treatment. J Med Virol 1997; 53:313-318. (Pubitemid 28228355)